Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

Fulvestrant and male breast cancer: a case series

(2012) F. Zagouri et al.   ANNALS OF ONCOLOGY

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

(2012) Holm Eggemann et al.   BREAST CANCER RESEARCH AND TREATMENT

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) S. Aebi et al.   ANNALS OF ONCOLOGY

Fulvestrant for advanced male breast cancer patients: a case series

(2011) G. Masci et al.   ANNALS OF ONCOLOGY

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

(2011) Judith M. Bliss et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

(2011) Meredith M Regan et al.   LANCET ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Male breast cancer: An update in diagnosis, treatment and molecular profiling

(2010) Susan Onami et al.   MATURITAS

Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated with Aromatase Inhibitors

(2010) C. Bighin et al.   ONCOLOGIST

Aromatase inhibition in male breast cancer patients: biological and clinical implications

(2009) J. Doyen et al.   ANNALS OF ONCOLOGY

Fulvestrant in advanced male breast cancer

(2009) J. R. de la Haba Rodriguez et al.   ANNALS OF ONCOLOGY